Introduction
Overexpression of epidermal growth factor receptor (EGFR) in autocrine growth-regulated carcinoma and malignant glioma cells is associated with the expression of mutated EGFR species as part of neoplastic progression (Nishikawa et al., 1994; Moscatello et al., 1995; Nagane et al., 1996; Huang et al., 1997; Frederick et al., 2000) . Among these EGFR variants, the 140-155 kDa EGFRvIII represents a relatively well-characterized oncoprotein with a major in-frame deletion involving exons 2-7 of the EGFR gene. Thus, the mutation eliminates most amino acids comprising subdomains I and II including the cysteine-containing EGF binding site (Nishikawa et al., 1994; Batra et al., 1995) . EGFRvIII is constitutively active, cannot bind EGF (Moscatello et al., 1996) , and is only minimally activated by EGF (Wong et al., 1992) . EGFRvIII is widely expressed in malignant glioma and carcinoma cells, including breast carcinoma, non-small-cell lung carcinoma, ovarian carcinoma and others Frederick et al., 2000) . Mechanistic studies to elucidate the unique functions of EGFRvIII have been limited by the fact that this receptor is only expressed in vivo and is rapidly downregulated in cultured tumor cells precluding detailed investigation (Bigner et al., 1990) . To date, most studies on EGFRvIII have focused on the definition of its transforming activity and its effects on downstream signal transduction pathways (Montgomery et al., 1995; Huang et al., 1997) . However, the role of EGFRvIII in cellular responses to genotoxic stresses, such as ionizing radiation or other cytotoxic cancer therapeutic agents, has been only minimally investigated.
We have recently demonstrated that ionizing radiation in the therapeutic dose range of 1-5 Gy leads to 2-5-fold increases of EGFR Tyr phosphorylation resulting in radiation-induced activation of the receptor. This stimulation of EGFR mediates, through the activation of the MAPK and PI3K pathways, a major cytoprotective response (Schmidt-Ullrich et al., 1996 Dent et al., 1999) that confers on cells enhanced radioresistance due to accelerated cell proliferation , an antiapoptotic response (Contessa et al., 2002) , and improved repair functions after radiation exposures (Lammering et al., 2001b, c) . Both of these responses represent probable underlying mechanisms that modulate the radiosensitivity of human tumor cells in vitro and in vivo upon single and repeated radiation exposures (Schmidt-Ullrich et al., 1996; Lammering et al., 2001a, b ).
In the current study, we have extended our investigation of EGFR wild-type (wt) function on cellular radiation responses to the potentially modulating effects by EGFRvIII. As EGFRvIII is not expressed in cultured cells, these mechanistic studies were performed in vitro in Chinese hamster ovary (CHO) cells transfected with EGFRwt and/or EGFRvIII expression plasmids using conditions that yielded similar expression levels for both receptors. In these cells, the effects of EGFRvIII expression on acute cellular radiation responses were examined including the modulation of cell survival and apoptosis in vitro. The studies yielded two novel findings expanding our understanding of EGFR responses to radiation and the interactions between EGFRvIII and other ERBB receptor Tyr kinases. Based on these results, EGFRvIII furnishes a stronger cytoprotective radiation response than EGFRwt, which is likely due to the greater activation of EGFRvIII after irradiation. This activation is also transmitted into more potent stimulation of MAPK and AKT, thus identifying EGFRvIII as a critical component in the ERBB signaling circuitry and in cellular radiation responses.
Results

EGFRvIII is unresponsive to EGF but is inhibited by AG1478
The experiments in this section were designed to define the level of EGFRvIII ligand independence (Moscatello et al., 1996) and the constitutive activity of the receptor for radiation response studies in consecutive sections. These studies were performed with CHO cells that were cotransfected with pbhAc.EGFRvIII and pCMV.EGFRwt to achieve similar protein levels, and the Tyr phosphorylation levels of EGFRwt and EGFRvIII were quantified after treatment with EGF and/or AG1478 for inhibition of EGFR Tyr kinase activity. Western blot analyses with an anti-EGFR mAb showed similar expression levels under these conditions ( Figure 1a ). Treatment of CHO cells, coexpressing (Figure 1c ). These data demonstrate the EGF independence of EGFRvIII activity and its sensitivity to Tyr kinase inhibition by AG1478.
Ligand-independent radiation-induced activation of EGFRvIII
The functional consequences of EGFRvIII expression on cellular radiation responses were examined in CHO.EGFRvIII cells, and the effects on downstream signal transduction pathways after irradiation were compared to those in CHO cells expressing EGFRwt alone (CHO.EGFRwt). Western blot analyses showed similar protein expression levels of EGFRvIII and EGFRwt 48 h after transfection using conditions described above (Figure 2a ). The EGFRvIII protein showed the typical electrophoretic pattern of two bands of previously reported sizes between 140 and 155 kDa ( Figure 1 ) (Nishikawa et al., 1994) (Figure 2c ). The response patterns of immediate radiation-induced activation of EGFRvIII or EGFRwt were very similar in CHO.EGFRvIII or CHO.EGFRwt cells, respectively, but the incremental maximum activation was significantly greater for EGFRvIII when compared to EGFRwt (P ¼ 0.003; Figure 2b ,c). Western blotting with an anti-EGFRvIII mAb revealed that both molecular weight species, the p140 and p155 protein, of EGFRvIII responded with similar increases in Tyr phosphorylation when compared to untreated controls ( Figure 2c ).
Radiation-induced activation of EGFRvIII mediates enhanced MAPK activation
Having identified EGFRvIII as a target of radiationinduced activation, we next explored the ability of EGFRvIII to transmit radiation signals into the MAPK cascade and compared the findings with the radiationinduced MAPK activation that was identified as an important downstream target of EGFRwt in previous studies from our laboratory Reardon et al., 1999; Schmidt-Ullrich et al., 2000) . Using conditions similar to those described for experiments shown in Figure 2 , CHO cells were transfected with pbhAc.EGFRvIII or pCMV.EGFRwt or subjected to mock (CHO.mock) transfection and irradiated 48 h later. Western blot analyses, as shown in Figure 2a , confirmed similar expression levels of EGFRvIII and EGFRwt. In cells expressing EGFRvIII, we found that 2 Gy induced a transient maximum 8.5-fold (P ¼ 0.009) activation of MAPK peaking at 2 min and returning to baseline levels within 30 min ( Figure 3a , left panel), thus EGFRvIII-mediated radioresistance G Lammering et al paralleling the phosphorylation response of the receptor (Figure 2c ). Pretreatment of cells with AG1478 reduced this response 475% to a twofold radiation-induced MAPK activation substantiating its dependence upon EGFRvIII function. By comparison, activation of EGFRwt after 2 Gy mediated a significant maximum 3.5-fold (P ¼ 0.045) activation of MAPK within 5 min ( Figure 3a , middle panel), a response that was also blunted by AG1478. The modest twofold activation of MAPK in CHO.mock cells was interpreted as a background response by these cells as it was not affected by treatment with AG1478 ( Figure 3a , right panel) and, therefore, was likely independent of EGFRvIII or EGFRwt expression. The different responses of CHO.EGFRvIII and CHO-EGFRwt cells to EGF treatment were impressively corroborated by the MAPK analyses. In CHO.EGFRvIII cells, EGF induced a modest but significant, 1.4-1.6-fold (P ¼ 0.02), activation of MAPK whereas CHO.EGFRwt cells yielded a fivefold increase (P ¼ 0.004; Figure 3b ). The radiationinduced activation of MAPK in CHO cells expressing EGFRvIII was greater than the EGF-induced activation of MAPK in cells expressing EGFRwt (Figure 3b ).
These data demonstrate that EGFRvIII expression has a profound effect of cellular radiation responses leading to potent receptor activation and transmitting amplified signals along the MAPK pathway.
Radiation-induced activation of EGFRvIII is also transmitted through the AKT/PI3K pathway
In other cell systems, the PI3K signal transduction pathway has been identified as another important downstream target of EGFRvIII (Moscatello et al., 1998) . We therefore investigated the ability of radiation (Figure 4a,b) . The radiationinduced activation of AKT in CHO cells expressing EGFRvIII was greater than the radiation-induced activation of AKT in cells expressing EGFRwt (Figure 4b ). These data show that radiation-induced activation of EGFRvIII is, at least in part, transmitted through the PI3K/AKT pathway.
Expression of EGFRvIII confers an enhanced cytoprotective response to ionizing radiation
To correlate radiation-induced activation of EGFRvIII with the radiosensitivity of CHO cells, we examined cell survival after single radiation doses of 2, 4 and 8 Gy using colony formation assay and comparing cells expressing EGFRvIII with cells expressing EGFRwt or mock-transfected cells. In addition, the contribution of EGFRvIII was examined through quantitative inhibition of EGFRvIII function using AG1478. As assessed by colony formation assays, CHO.EGFRvIII cells were less sensitive to varying single radiation exposures than CHO.EGFRwt or mock-transfected CHO cells (Po0.001; Figure 5a ). EGFRvIII mediated a significantly stronger cytoprotective response to radiation than EGFRwt (Po0.001), as reflected by a dose-enhancement ratio (DER) of 1.61 relative to 1.32 for control relative to CHO.EGFRvIII and CHO.EGFRwt cells, respectively. As demonstrated in Figure 5b , expression of EGFRvIII conferred an almost twofold increase in clonogenic survival after exposure to 4 Gy, indicating a doubling of radioresistance in this assay conferred by EGFRvIII expression compared to CHO.mock cells (Figure 5b , right panel). AG1478 treatment almost completely eliminated this increase in radioresistance of CHO.EGFRvIII cells (Figure 5b ), again indicating that the cytoprotective response is initiated at the level of EGFRvIII. Figure 3 ). The effects of EGFRvIII or EGFRwt proteins were assessed through controls from cells pretreated with AG1478 to eliminate receptor Tyr phosphorylation completely. Treatments were 48 h after transfection using conditions described under EGFRvIII-mediated radioresistance G Lammering et al
Expression of EGFRvIII inhibits radiation-induced apoptosis
We further investigated the effects of EGFRvIII and EGFRwt expression on the radiation-induced apoptosis in CHO cells 24 h following ionizing radiation exposure (Kennedy et al., 1999; Contessa et al., 2002) . By comparison, irradiation of CHO.EGFRvIII cells with a single dose of 4 Gy induced only a minimal 1.1-fold increase (P ¼ NS) in apoptosis relative to unirradiated controls. In contrast, exposure of both CHO.EGFRwt and CHO.mock cells to 4 Gy significantly enhanced apoptosis by an average of 1.9-fold (P ¼ 0.015; Figure 6 ). These results demonstrate that the presence of EGFRvIII, but not EGFRwt, counteracts radiation-induced apoptosis in CHO cells, and suggest that the antiapoptotic response is mediated through radiation-induced EGFRvIII activation.
Discussion
The data presented in this study provide new insights into the biological functions of the constitutively active EGFRvIII. To date, mechanistic studies on this naturally occurring truncated receptor have been limited since its spontaneous expression is only seen in vivo in naturally occurring tumors or xenografts of human tumor cells (Lammering et al., 2001a) and is rapidly lost in vitro (Bigner et al., 1990) . In extension of previous studies on the role of EGFRvIII as an oncoprotein (Ekstrand et al., 1994; Nishikawa et al., 1994; Batra et al., 1995; Nagane et al., 1996; Huang et al., 1997) , have started to define its involvement in cellular responses to genotoxic stress, such as ionizing radiation. Our results define EGFRvIII as an important response molecule that is unresponsive to EGF (Huang et al., 1997) but is activated by radiation to a greater extent than EGFRwt. Since intensified responses of EGFRvIII are also transmitted as amplified signals at the level of MAPK (Montgomery et al., 1995) and AKT, EGFRvIII can be expected to mediate a more powerful cytoprotective response after irradiation than we have previously demonstrated for EGFRwt Schmidt-Ullrich et al., 2000; Lammering et al., 2001a, b) .
Studies in CHO cells were performed because of the high transfection efficiencies (Ekstrand et al., 1994) , and the ability to control expression levels of both EGFRvIII and EGFRwt. The independent expression of both EGFR molecules was required to define their relative roles in generating activation responses, as quantified by receptor Tyr phosphorylation, after exposure of cells to growth factor ligands or ionizing radiation. While we have characterized the responses for EGFRwt in other cells, it was important to quantify the potential contribution of the constitutively active EGFRvIII to cytoprotective responses in the same cell system. In addition to the controlled expression of EGFRwt and EGFRvIII, we also confirmed their effects on cellular signaling and survival responses using the EGFRspecific tyrphostin kinase inhibitor AG1478 (Han et al., 1996) .
Irradiation of CHO cells, expressing similar levels of EGFRwt or EGFRvIII, demonstrated independent activation of each receptor (Schmidt-Ullrich et al., 1996 . However, the 4.3-fold stimulation of EGFRvIII was consistently higher, yielding a significant 1.8-fold (P ¼ 0.03) greater activation relative to EGFRwt. The fundamental difference in response of the receptors was demonstrated upon exposure of cells to EGF that induced a 3.3-fold activation of EGFRwt but no significant enhancement in Tyr phosphorylation of EGFRvIII most likely due to deletions in the COOHterminal EGF-binding domain (Wong et al., 1992) . A minor activation response through interaction with other ERBB receptors cannot be excluded (Chu et al., 1997; O'Rourke et al., 1998b) . The radiation response of EGFRvIII may be of considerable importance since we have demonstrated in previous studies that EGFR furnishes a significant cytoprotective response conferring cellular radioresistance that is mediated by radiation-induced proliferation and antiapoptosis , and by direct radiosensitization (Lammering et al., 2001a, b) most likely due to transcriptioncontrolled increased expression of repair proteins, including PCNA (Amorino et al., 2002; Amorino et al., unpublished results) . In line with previous experiences, the relative importance of radiation-induced activation of both EGFRwt and EGFRvIII is adequately studied by exposure of cells to AG1478 since this treatment almost completely inhibited activation of different EGFR species and, therefore, can be expected to block downstream signaling (Han et al., 1996; Schmidt-Ullrich et al., 1997;  Figure 1) .
The radiation-induced activation signals from EGFR are transmitted through the MAPK pathway Reardon et al., 1999; Lammering et al., 2001b) . This is affirmed by our finding that cells expressing EGFRvIII produced a minimum 2.5-fold greater activation of MAPK than cells expressing EGFRwt (Figure 3) . The close functional link between EGFR Tyr phosphorylation and MAPK activation in transfected CHO cells was corroborated by the almost complete inhibition of MAPK by AG1478, confirming observations in NIH3T3 and U87MG cells that were transfected with EGFRvIII (Montgomery et al., 1995; Moscatello et al., 1995; Han et al., 1996) . Since we have previously identified MAPK as a downstream effector of the EGFR-mediated cytoprotective response after irradiation, it can be expected that EGFRvIII expression in cells enhances this response relative to EGFRwt. These conclusions may apply to PI3K, which demonstrates higher activity levels in EGFRvIII expressing cells (Moscatello et al., 1998) and acts in concert with MAPK in transmitting EGFR signals after irradiation to enhance antiapoptotic responses (Contessa et al., 2002) .
While activation of MAPK and PI3K could predict the decreased radiosensitivity of cells, the contribution of EGFRvIII or EGFRwt to cellular radioresistance was more directly quantified by clonogenic survival of CHO.EGFRvIII and CHO.EGFRwt cells. The expression of EGFRvIII raised the surviving fraction in a radiation dose-dependent manner, demonstrating that CHO cells expressing EGFRvIII were significantly more resistant than their counterparts transfected under identical conditions with EGFRwt or control plasmids (Po 0.001). After 2 Gy the surviving fraction increased from approximately 50 to 85% (1.7-fold), an effect completely reversed upon inhibition of the receptor by AG1478. This difference changed to a 2.5-fold increase in relative radioresistance of EGFRvIII expressing cells after 4 Gy. These data represent the most direct demonstration that radiation-induced activation of EGFR species provides a strong cytoprotective signal with increased radioresistance through enhanced proliferation and repair Reardon et al., 1999; Lammering et al., 2001a) . From studies on p185neu (ERBB2), the impact of ERBB receptors on cellular radiosensitivity may not be limited to EGFR and its mutants (O'Rourke et al., 1997 (O'Rourke et al., , 1998a , but likely depend upon the entire ERBB expression profile of a given tumor cell (Bowers et al., 2001; Lammering et al., 2001a; Contessa et al., 2002) .
In summary, this study demonstrates the importance of EGFRvIII, likely expressed in many human tumors in vivo, in tumor cell radiation responses. Possibly due to its state of constitutive activation, EGFRvIII produces a greater activation signal after irradiation of cells than previously described for EGFRwt. Therefore, EGFRvIII can be expected to also produce a more pronounced cytoprotective response mediated by amplified activation of downstream effectors such as MAPK and PI3K. These findings therefore imply that in some carcinoma and glioma cell types, therapeutic strategies targeting EGFR need to assure activity against EGFRvIII in order to achieve most effective radiosensitization of human carcinoma and malignant gliomas.
Materials and methods
Reagents and cell lines
Unless otherwise specified, all reagents were from Sigma Chemical Co. (St Louis, MO, USA). All electrophoresis reagents were from BioRad (Hercules, CA, USA); the EGFR tyrosine kinase inhibitor tyrphostin AG1478 was from Calbiochem (San Diego, CA, USA); EGF was purchased from Sigma Chemical Co. (St Louis, MO, USA). Media and antibiotics were from GIBCO-BRL (Rockville, MD, USA), and fetal bovine serum (FBS) was from Intergen (Purchase, NY, USA). The following immunological reagents were used: the immunoprecipitating anti-EGFR monoclonal antibody (mAb) from Transduction Laboratories (Lexington, KY, USA), the anti-Tyr phosphorylation mAb, Ab2, from Onco-gene Science (Cambridge, MA, USA), the anti-EGFR mAb for Western blotting, Ab14, from Neomarkers (Fremont, CA, USA), and anti-EGFRvIII mAb, DH8.3 from Abcam (Cambridge, UK). The secondary Ab, an anti-mouse alkaline phosphatase conjugate, was from Promega (Madison, WI, USA). Other reagents included Protein G Plus/Protein A Agarose from Oncogene Science (Cambridge, MA, USA), mAb to p42/44 MAPK (ERK2), C-14, and to AKT (sc-1619) both as agarose conjugates from Santa Cruz (Santa Cruz, CA, USA). Myelin basic protein (MBP) as substrate for MAPK (Sigma Chemical Co., St Louis, MO, USA) or AKT (Santa Cruz, Santa Cruz, CA, USA) was used as stocks of 10 and 5 mg/ml in H 2 O, respectively. The pCL6 plasmid was used as an empty vector control. The EGFRwt cDNA was kindly provided by A Ullrich (Max-Planck-Institute for Biochemistry, Martinsried, Germany), and the phbAc.EGFRvIII expression plasmid was obtained from D Bigner (Department of Pathology, Duke University, Durham, NC, USA) (Batra et al., 1995) .
The CHO cell line and the A431 squamous carcinoma cell line were obtained from the American Type Tissue Collection (ATTC; Rockville, MD, USA). All cells were maintained at 371C in 95% air/5% CO 2 except for irradiation, which was performed at 201C in air. The CHO and the A431 cell lines were maintained in RPMI1640 medium containing 5% FBS (RPMI/5FBS) and antibiotics (penicillin/streptomycin). Only mycoplasma-free cultures were employed as assured by monthly testing.
Transient transfection of CHO cells
CHO cells were routinely seeded at 1.5 Â 10 5 cells per 60-mm dish. Cells were cultured for a total of 5 days in RPMI/5FBS. On day 3, transient transfections were performed. The conditions for optimal transfection efficiency were determined by Western analysis of EGFRvIII and EGFRwt protein expression levels 48 h after transfecting the CHO cells with varying amounts of the expression plasmids. In parallel transfection, experiments with identical amounts of a pK7.GFP (green fluorescence protein) plasmid, provided by I. Macarra (University of Virginia, Charlottesville, VA, USA), re performed for microscopic quantification of transfection efficiency of GFP-positive cells after 48 h. Optimal conditions yielding 490% transfection efficiencies were established with 0.5 mg of the phbAc.EGFRvIII or pCMV.EGFRwt expression plasmid and 1.5 mg of the empty vector using Lipofectamine Plust as a carrier (GIBCO-BRL, Gaithersburg, MD, USA). For mock transfections, referred to as CHO.mock, 2 mg of the empty vector was transfected under identical conditions. For the development of CHO cells coexpressing EGFRvIII and EGFRwt, varying amounts of the pCMV.EGFRwt DNA were cotransfected with 0.3 mg of the phbAc.EGFRvIII DNA and varying amounts of the empty vector keeping the total amount of DNA at 2 mg.
Cell treatments and irradiation
Cell treatments and irradiation experiments were performed on day 5, 48 h after transfection. Pretreatment of cells was with 5 mM AG1478 for 30 min. EGF exposures of cells was at 10 or 100 ng/ml for 5 min except for EGF treatment for AKT assays, which was for 15 min. For all irradiation experiments, cells were exposed to single doses of ionizing radiation at a dose rate of 1.8 Gy/min using a 60 Co source. In time course experiments, cells were irradiated and incubated at 371C for the times specified. Thereafter, media were removed and cells were washed once in ice-cold PBS, rapidly frozen on dry ice and stored at À801C until further processing.
Immunoprecipitation and Western blot analysis
Immunoprecipitation and Western blotting experiments were performed as previously described (Schmidt-Ullrich et al., 1997; Contessa et al., 1999; Reardon et al., 1999) . Briefly, frozen cells were lysed in ice-cold lysis buffer, and cell lysis was facilitated by repeated passage through a 20-gauge needle. The protein levels in supernatants obtained after centrifugation (16 000 r.p.m., microcentrifuge) were quantified with a BioRad protein assay kit (Bio-Rad Labs, Richmond, CA, USA). Equal amounts of cellular protein were employed for Western blotting of EGFRwt, EGFRvIII and Tyr phosphorylation or for immunoprecipitation using anti-EGFR mAb at 41C for 90 min followed by incubation with Protein G Plus/Protein A Agarose for 45 min. Immunoprecipitates were washed once in lysis buffer and twice in PBS. After size fractionation in 6% SDS-polyacrylamide gels, proteins were transferred electrophoretically onto nitrocellulose membranes (BioRad, Hercules, CA, USA). The membranes were then incubated with primary mAb followed by incubation with peroxidase-conjugated secondary mAb. For visualization, bands were developed with the CDP-Star kit (Tropix, Inc., Bedford, MA, USA). For analysis of Tyr phosphorylation levels autoradiograms were quantified using Sigma Scan software (Jandel Scientific, San Rafael, CA, USA) (Schmidt-Ullrich et al., 1996) .
Immune complex kinase assays
Identical protein aliquots from cell lysates were incubated with anti-ERK2 or anti-AKT mAbs at 41C for 3 h or overnight, respectively. After washing once with lysis buffer and twice with 1 Â kinase buffer, 25 mm b-glycerophosphate, pH 7.4, 15 mm MgCl 2 , immunoprecipitates were suspended in 40 ml H 2 O containing the appropriate substrates, consisting of 20 mg MBP for MAPK or 1 mg AKT substrate for AKT. The kinase reaction was initiated by the addition of 10 ml of 5 Â kinase buffer, 500 mm ATP, and [g À32 P]ATP (5000 c.p.m./pmol) (ICN Biomedicals, Irvine, CA, USA) and maintained at 371C for 30 min. Aliquots of the assay mixture were placed on P81 paper and nonspecific binding of [g À32 P]ATP was removed by extensive washing in 180 mm phosphoric acid. Incorporation of 32 P into bound MBP or AKT substrate was quantified by absorption to P81 followed by liquid scintillation spectroscopy (Beckman Instruments Inc., Schaumburg, IL, USA) .
Colony formation assay
Irradiation of cells was 48 h after transfection at doses of 2, 4 and 8 Gy. Cells were incubated for an additional 24 h, harvested and plated for clonogenic survival. The number of cells was adjusted to generate 50-300 colonies per dish at each radiation dose and plated into 60-mm culture dishes. Cells were maintained at 371C with 5% CO 2 for 12 days, stained with crystal violet, and colonies containing X50 cells were counted to determine surviving fractions (Lammering et al., 2001a, b) .
Measurement of apoptosis
Apoptosis rates were determined 24 h following exposure to 4 Gy. The culture medium and trypsinized cells were centrifuged and resuspended in methanol : acetic acid (3 : 1). The cells were then washed twice in methanol : acetic acid, pipetted onto microscopic slides and allowed to air dry. Following Giemsa staining, averages of 1500 cells were counted per slide to determine the percentage of apoptosis.
Statistical analysis
The effects of various treatments were compared using Student's t-test. Statistical comparisons between clonogenic survival curves were carried out by use of the F-test. The radiation DERs for mock control cells compared to conditions of EGFRvIII or EGFRwt expression were derived from the ratios of the dose for a survival of 37% (D 37 ) for the survival curves for EGFRvIII or EGFRwt corresponding cells and the mock control survival curves in single-dose clonogenic survival assays. Differences yielding a P-value of o0.05 were considered statistically significant. All values and means shown are 7s.d. (standard deviation), unless otherwise specified.
